StockNews.com Initiates Coverage on InspireMD (NYSE:NSPR)

Research analysts at StockNews.com assumed coverage on shares of InspireMD (NYSE:NSPR) in a research note issued to investors on Wednesday. The firm set a “sell” rating on the stock.

Separately, Lake Street Capital initiated coverage on InspireMD in a research note on Wednesday, December 11th. They issued a “buy” rating and a $5.00 target price for the company.

InspireMD Trading Up 5.8 %

Shares of NYSE NSPR opened at $2.57 on Wednesday. The firm has a fifty day simple moving average of $2.83 and a two-hundred day simple moving average of $2.73. InspireMD has a 12 month low of $1.81 and a 12 month high of $3.42. The firm has a market capitalization of $67.03 million, a PE ratio of -3.43 and a beta of 0.99.

InspireMD (NYSE:NSPR) last released its quarterly earnings results on Tuesday, November 12th. The company reported ($0.16) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.20) by $0.04. The company had revenue of $1.81 million during the quarter, compared to the consensus estimate of $1.74 million. InspireMD had a negative net margin of 413.96% and a negative return on equity of 69.42%. During the same period in the prior year, the firm earned ($0.15) earnings per share. On average, sell-side analysts predict that InspireMD will post -0.79 earnings per share for the current year.

Hedge Funds Weigh In On InspireMD

A number of institutional investors and hedge funds have recently made changes to their positions in the business. Affiance Financial LLC boosted its position in shares of InspireMD by 2.9% in the 4th quarter. Affiance Financial LLC now owns 189,122 shares of the company’s stock worth $497,000 after purchasing an additional 5,376 shares in the last quarter. Parkman Healthcare Partners LLC purchased a new position in InspireMD during the third quarter valued at $279,000. Finally, Legato Capital Management LLC bought a new stake in InspireMD in the fourth quarter worth $47,000. Institutional investors own 44.78% of the company’s stock.

About InspireMD

InspireMD, Inc, a medical device company, focuses on the development and commercialization of MicroNet stent platform technology for the treatment of vascular and coronary diseases in Europe, Latin America, the Middle East, and Asia Pacific. The company offers CGuard carotid embolic prevention system (EPS) for use in carotid artery applications; CGuard Prime Stent System, a mesh-covered self-expanding carotid stent; and SwitchGuard NPS, a non-invasive transcarotid artery revascularization device; as well as treating acute stroke with tandem lesions.